Literature DB >> 24056138

An 8-year follow-up study of 221 consecutive hip fracture patients in Finland: analysis of reoperations and their direct medical costs.

P Lüthje1, T Helkamaa, I Nurmi-Lüthje, J-P Kaukonen, M Kataja.   

Abstract

BACKGROUND: Some hip fracture patients need one or more reoperations because of complications following initial operative treatment. AIMS: The aim of this study was to identify all further surgical interventions in a cohort of patients with hip fractures over a period of 8 years after index fracture. Immediate direct costs of these reoperations were also calculated.
MATERIAL AND METHODS: This retrospective study investigated 221 consecutive patients with hip fractures operated on at two different hospitals in southeastern Finland. The study period in hospital A was from 1 February 2003 to 31 January 2004, and in hospital B from 1 February 2003 to 30 April 2004. About 50% were femoral neck fractures, 41% trochanteric fractures, and 9% subtrochanteric fractures. Patients' medical records were checked from the hospital records and confirmed manually. Short- and long-term complications were recorded. Survival analysis was performed using a life-table method. The actual costs for reoperations and other further procedures for each patient were calculated using diagnosis-related groups-based costs for both hospitals in 2012.
RESULTS: A total of 20 patients (9%) needed reoperations. Overall, 10 patients (8.9%) with a femoral neck fracture (n = 112), 8 patients (8.7%) with trochanteric fracture (n = 92), and 2 patients (10.5%) with subtrochanteric fracture (n = 19) were reoperated on. The median interval between the primary operation of the acute hip fracture (n = 20) and the first reoperation was about 300 days (range: 2 weeks to 82 months). Among the women reoperated on, the excess mortality was lower than among those undergoing a single operation. The median costs of treatment per patient with one or more reoperations were €13,422 in hospital A (range: €1616-€61,755), €11,076 in hospital B (range: €1540-€17,866), and €12,850 in the total study group (p = 0.43). In the case of infections (3 patients), the mean costs per patient were €28,751 (range: €11,076-€61,755).
CONCLUSIONS: Almost 10% of hip fracture patients required reoperations, and these reoperations caused significant direct costs to health care. However, direct costs account for only approximately 25% of the first year's total costs. These costs should be taken into account when evaluating the economics of hip fractures and the burden of health care.

Entities:  

Keywords:  Hip fracture; cost; long-term follow-up; postoperative complication; reoperation; survival

Mesh:

Year:  2013        PMID: 24056138     DOI: 10.1177/1457496913494726

Source DB:  PubMed          Journal:  Scand J Surg        ISSN: 1457-4969            Impact factor:   2.360


  4 in total

1.  Predictors for secondary hip osteoarthritis after acetabular fractures-a pelvic registry study.

Authors:  Mika F Rollmann; Jörg H Holstein; Tim Pohlemann; Steven C Herath; Tina Histing; Benedikt J Braun; Hagen Schmal; Guy Putzeys; Ivan Marintschev; Emin Aghayev
Journal:  Int Orthop       Date:  2018-09-29       Impact factor: 3.075

Review 2.  Post-discharge complications in postoperative patients with hip fracture.

Authors:  Umi Istianah; Intansari Nurjannah; Rahadyan Magetsari
Journal:  J Clin Orthop Trauma       Date:  2020-10-24

3.  Positive Effects of a Sufficient Pre-fracture Serum Vitamin D Level on the Long-Term Survival of Hip Fracture Patients in Finland: A Minimum 11-Year Follow-Up.

Authors:  Ilona Nurmi-Lüthje; Peter Lüthje; Juha-Pekka Kaukonen; Matti Kataja
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

4.  Medical and economic consequences of perioperative complications in older hip fracture patients.

Authors:  Tom Knauf; Juliana Hack; Juliane Barthel; Daphne Eschbach; Carsten Schoeneberg; Steffen Ruchholtz; Benjamin Buecking; Rene Aigner
Journal:  Arch Osteoporos       Date:  2020-11-06       Impact factor: 2.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.